Finally, since tumor mutation burden (TMB) is currently being investigated as a biomarker for durable response to life-extending cancer immunotherapies33, we also tested the association of germline RDV load in CPD, DDR, SCD and FA gene-sets with TMB for each cancer type with solid tumors (Supplementary Data 7). This evidence concerns the gene SCD and neoplasm.